At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Jun 4, 2026 at 17:12 ET
NRx Pharmaceuticals closed an underwritten public offering of common stock at $3.50 per share, raising approximately $22.3 million in gross proceeds. The proceeds will be used for working capital and general corporate purposes to support the company's clinical-stage pipeline for CNS disorders.
- Closed underwritten public offering of common stock at $3.50 per share
- Gross proceeds of approximately $22.3 million
- Proceeds to be used for working capital and general corporate purposes
- BTIG and Lucid Capital Markets acted as bookrunners
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access